Euroopan unioni - malta - EMA (European Medicines Agency)

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - Ħnieżer - vaċċini - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.

Euroopan unioni - malta - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - deucravacitinib - psorajiżi - immunosoppressanti - treatment of moderate-to-severe plaque psoriasis in adults.

Euroopan unioni - malta - EMA (European Medicines Agency)

sanofi belgium - alemtuzumab - sklerosi multipla - immunosuppressanti selettivi - lemtrada huwa indikat għall-pazjenti adulti bl-relapsing-remitting multipli sclerosis (rrms) bil-marda attiva definiti mill-karatteristiċi kliniċi jew tal-immaġnar.

Euroopan unioni - malta - EMA (European Medicines Agency)

novo nordisk a/s - turoctocog alfa - hemofilja a - fattur viii tal-koagulazzjoni - trattament u profilassi ta 'fsada f'pazjenti b'emofilja a (nuqqas konġenitali ta' fattur viii). novoeight jista 'jintuża għall-etajiet kollha.

Euroopan unioni - malta - EMA (European Medicines Agency)

novartis europharm limited  - onasemnogene abeparvovec - atrofija muskolari, spinali - mediċini oħra għal disturbi fis-sistema muskoloskeletali - zolgensma huwa indikat għall-kura ta': pazjenti b'5q spinali-atrofija muskolari (sma) bil-bi-allelic mutazzjoni fil-smn1 tal-ġeni u l-dijanjosi klinika tal-sma tat-tip 1, orpatients mal-5q sma bil-bi-allelic mutazzjoni fil-smn1-ġeni u sa 3 kopji ta'l-smn2 ġene.

Euroopan unioni - malta - EMA (European Medicines Agency)

novartis europharm limited  - siponimod-aċidu fumariku - l-isklerożi multipla, sklerożi multipla li tirkadi u tbatti - immunosuppressanti selettivi - mayzent huwa indikat għall-kura ta ' pazjenti adulti bi sklerożi multipla progressiva sekondarja (spms), bil-marda attiva muri mill-irkadar jew l-immaġini tal-karatteristiċi ta'l-attività infjammatorja.

Euroopan unioni - malta - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - elotuzumab - majloma multipla - aġenti antineoplastiċi - empliciti huwa indikat, flimkien ma 'lenalidomide u dexamethasone għall-kura ta' majeloma multipla f'pazjenti adulti li jkunu rċevew mill-anqas terapija waħda qabel (ara sezzjonijiet 4. 2 u 5.

Euroopan unioni - malta - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidine - lewkimja, mijelojda, akuta - aġenti antineoplastiċi - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Euroopan unioni - malta - EMA (European Medicines Agency)

immedica pharma ab - glycerol phenylbutyrate - disturbi taċ-Ċiklu ta 'l-urea, inborn - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - ravicti huwa indikat għall-użu bħala terapija aġġuntiva għall-kroniku tal-ġestjoni ta 'pazjenti bil-urea disturbi fiċ-ċiklu (ucds) inklużi n-nuqqasijiet tal-carbamoyl phosphate-synthase-i (cps), ornithine carbamoyltransferase (otc), argininosuccinate synthetase (ass), argininosuccinate lyase (asl), arginase i (arg) u ornithine translocase defiċjenza hyperornithinaemia-iperammonemija homocitrullinuria sindromu (hhh) li ma jistgħux ikunu ġestiti mill-restrizzjoni ta' proteini tad-dieta u/jew l-aċidu amminiku supplimentazzjoni waħdu. ravicti għandhom jiġu użati mal-restrizzjoni ta ' proteini tad-dieta u, f'xi każijiet, supplimenti tad-dieta (e. , amino acids essenzjali, arginine, citrulline, supplimenti ta 'kaloriji mingħajr proteini).

Euroopan unioni - malta - EMA (European Medicines Agency)

camurus ab - buprenorphine - disturbi relatati ma 'opjojdi - drogi oħra tas-sistema nervuża - it-trattament ta ' dipendenza opjojd fi ħdan il-qafas mediku, soċjali u psikoloġiku trattament. it-trattament huwa intenzjonat għall-użu fl-adulti u l-adolexxenti li għandhom 16-il sena jew aktar.